(R)-Indan-1-yl-[6-((E)-styryl)-4H-benzo[d][1,3]oxazin-2-yl]-amine | 1214249-59-8

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: (R)-Indan-1-yl-[6-((E)-styryl)-4H-benzo[d][1,3]oxazin-2-yl]-amine
• 英文别名: N-[(1R)-2,3-dihydro-1H-inden-1-yl]-6-[(E)-2-phenylethenyl]-1,4-dihydro-3,1-benzoxazin-2-imine
• CAS: 1214249-59-8
• 化学式: C₂₅H₂₂N₂O
• 分子量: 366.462
• InChiKey: BLAUQWXONJQKJH-NFPSEPLVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.5
• 重原子数：
  28
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.16
• 拓扑面积：
  33.6
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  苯乙烯 、 (6-bromo-4H-benzo[d][1,3]oxazin-2-yl)-(R)-indan-1-yl-amine 在 palladium diacetate 、 三(邻甲基苯基)磷 三乙胺 作用下， 以 乙腈 为溶剂， 反应 23.0h， 以16%的产率得到(R)-Indan-1-yl-[6-((E)-styryl)-4H-benzo[d][1,3]oxazin-2-yl]-amine
  参考文献：
  名称：

  6-SUBSTITUTED BENZOXAZINES

  摘要：

  本发明涉及公式(I)的6-取代苯并噁嗪衍生物，其中X、Y、R1和R2如本文所述，其制备方法，以及含有它们的药物组合物。本发明的活性化合物是5-HT5A受体拮抗剂，在预防和/或治疗抑郁症、焦虑障碍、精神分裂症、恐慌障碍、广场恐惧症、社交恐惧症、强迫性障碍、创伤后应激障碍、疼痛、记忆障碍、痴呆症、进食行为障碍、性功能障碍、睡眠障碍、药物滥用、运动障碍、帕金森病、精神障碍或胃肠道障碍的预防和/或治疗中有用。

  公开号：

  US20100063037A1

文献信息

• 6-substituted benzoxazines
  申请人：Hoffmann-La Roche Inc.

  公开号：US08163740B2

  公开（公告）日：2012-04-24

  The present invention is concerned with 6-substituted benzoxazine derivatives of formula (I) wherein X, Y, R1 and R2 are as described herein, their manufacture, and pharmaceutical compositions containing them. The active compounds of the present invention are 5-HT5A receptor antagonists, useful in the prevention and/or treatment of depression, anxiety disorders, schizophrenia, panic disorders, agoraphobia, social phobia, obsessive compulsive disorders, post-traumatic stress disorders, pain, memory disorders, dementia, disorders of eating behaviors, sexual dysfunction, sleep disorders, abuse of drugs, motor disorders, Parkinson's disease, psychiatric disorders or gastrointestinal disorders.

  本发明涉及式(I)的6-取代苯并噁唑衍生物，其中X、Y、R1和R2如本文所述，它们的制备方法以及含有它们的制药组合物。本发明的活性化合物是5-HT5A受体拮抗剂，可用于预防和/或治疗抑郁症、焦虑症、精神分裂症、惊恐障碍、广场恐惧症、社交恐惧症、强迫症、创伤后应激障碍、疼痛、记忆障碍、痴呆症、饮食行为障碍、性功能障碍、睡眠障碍、药物滥用、运动障碍、帕金森病、精神障碍或胃肠障碍。
• 6-SUBSTITUTED BENZOXAZINES AS 5-HT-5A RECEPTOR ANTAGONISTS
  申请人：F. Hoffmann-La Roche AG

  公开号：EP2328880B1

  公开（公告）日：2012-10-31
• US8163740B2
  申请人：——

  公开号：US8163740B2

  公开（公告）日：2012-04-24
• [EN] 6-SUBSTITUTED BENZOXAZINES<br/>[FR] BENZOXAZINES À SUBSTITUTION EN 6
  申请人：HOFFMANN LA ROCHE

  公开号：WO2010026110A2

  公开（公告）日：2010-03-11

  The present invention is concerned with 6-substituted benzoxazine derivatives of formula (I), wherein X, Y, R1 and R2 are as described herein, as well as their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are 5-HT5A receptor antagonists, useful in the prevention and/or treatment of depression, anxiety disorders, schizophrenia, panic disorders, agoraphobia, social phobia, obsessive compulsive disorders, post-traumatic stress disorders, pain, memory disorders, dementia, disorders of eating behaviors, sexual dysfunction, sleep disorders, abuse of drugs, motor disorders, Parkinson's disease, psychiatric disorders or gastrointestinal disorders.
• 6-SUBSTITUTED BENZOXAZINES
  申请人：Kolczewski Sabine

  公开号：US20100063037A1

  公开（公告）日：2010-03-11

  The present invention is concerned with 6-substituted benzoxazine derivatives of formula (I) wherein X, Y, R 1 and R 2 are as described herein, their manufacture, and pharmaceutical compositions containing them. The active compounds of the present invention are 5-HT 5A receptor antagonists, useful in the prevention and/or treatment of depression, anxiety disorders, schizophrenia, panic disorders, agoraphobia, social phobia, obsessive compulsive disorders, post-traumatic stress disorders, pain, memory disorders, dementia, disorders of eating behaviors, sexual dysfunction, sleep disorders, abuse of drugs, motor disorders, Parkinson's disease, psychiatric disorders or gastrointestinal disorders.

  本发明涉及公式(I)的6-取代苯并噁嗪衍生物，其中X、Y、R1和R2如本文所述，其制备方法，以及含有它们的药物组合物。本发明的活性化合物是5-HT5A受体拮抗剂，在预防和/或治疗抑郁症、焦虑障碍、精神分裂症、恐慌障碍、广场恐惧症、社交恐惧症、强迫性障碍、创伤后应激障碍、疼痛、记忆障碍、痴呆症、进食行为障碍、性功能障碍、睡眠障碍、药物滥用、运动障碍、帕金森病、精神障碍或胃肠道障碍的预防和/或治疗中有用。